Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
- Authors
- Welslau, M.; Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I; Illes, A.; de la Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E. J.; Lee, J. H.; Wang, D.; Patel, P.; Quah, C.; Jurczak, W.
- Issue Date
- Oct-2020
- Publisher
- KARGER
- Citation
- ONCOLOGY RESEARCH AND TREATMENT, v.43, no.SUPPL 4, pp.71 - 72
- Journal Title
- ONCOLOGY RESEARCH AND TREATMENT
- Volume
- 43
- Number
- SUPPL 4
- Start Page
- 71
- End Page
- 72
- ISSN
- 2296-5270
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Lee, Jae Hoon
- College of Medicine (Department of Medicine)